The Patent Finder

Maintenance fees coming due

Immatics Biotechnologies GmbH

197 maintenance fees come due in the 12 months from Nov 21, 2026, the next on Nov 21, 2026. Unpaid by May 21, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5 and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the six month grace period that follows.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusFee dueLapses if unpaidExpiresConfidence
US 10,293,036Peptides and Combination of Peptides for Use in Immunotherapy Against NHL and Other Cancers
In force
Fee due Nov 21, 2026
Lapses if unpaid May 21, 2027
 · High confidence
Immatics Biotechnologies GmbHIn forceNov 21, 2026May 21, 2027High confidence
US 11,655,280Immunotherapy with B*07 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
In force
Fee due Nov 23, 2026
Lapses if unpaid May 24, 2027
 · High confidence
Immatics Biotechnologies GmbHIn forceNov 23, 2026May 24, 2027High confidence
US 11,655,281Immunotherapy with B*07 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
In force
Fee due Nov 23, 2026
Lapses if unpaid May 24, 2027
 · High confidence
Immatics Biotechnologies GmbHIn forceNov 23, 2026May 24, 2027High confidence
US 11,667,685B*44 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
In force
Fee due Dec 6, 2026
Lapses if unpaid Jun 7, 2027
 · High confidence
Immatics Biotechnologies GmbHIn forceDec 6, 2026Jun 7, 2027High confidence
US 10,314,896Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Cancers
In force
Fee due Dec 11, 2026
Lapses if unpaid Jun 11, 2027
 · High confidence
Immatics Biotechnologies GmbHIn forceDec 11, 2026Jun 11, 2027High confidence
US 10,314,897Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Cancers
In force
Fee due Dec 11, 2026
Lapses if unpaid Jun 11, 2027
 · High confidence
Immatics Biotechnologies GmbHIn forceDec 11, 2026Jun 11, 2027High confidence
US 10,314,898Novel Peptides and Combination of Peptides for Use in Immunotherapy Against NHL and Other Cancers
In force
Fee due Dec 11, 2026
Lapses if unpaid Jun 11, 2027
 · High confidence
Immatics Biotechnologies GmbHIn forceDec 11, 2026Jun 11, 2027High confidence
US 10,314,899Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers
In force
Fee due Dec 11, 2026
Lapses if unpaid Jun 11, 2027
 · High confidence
Immatics Biotechnologies GmbHIn forceDec 11, 2026Jun 11, 2027High confidence
US 10,316,062Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
In force
Fee due Dec 11, 2026
Lapses if unpaid Jun 11, 2027
 · Medium confidence
Immatics Biotechnologies GmbHIn forceDec 11, 2026Jun 11, 2027Medium confidence
US 10,316,063Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
In force
Fee due Dec 11, 2026
Lapses if unpaid Jun 11, 2027
 · Medium confidence
Immatics Biotechnologies GmbHIn forceDec 11, 2026Jun 11, 2027Medium confidence
187 more maintenance fees coming due in the 12 months from Nov 21, 2026 · Pro
10 of 197 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Upgrade to Pro
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited